The Management of Patients Diagnosed with Incidental Prostate Cancer: Narrative Review

References

• Karami H, Hassanzadeh-hadad A, Fallah-karkan M. Comparing monotherapy with tadalafil or tamsulosin and their combination therapy in men with benign prostatic hyperplasia: a randomized clinical trial. Urol J. 2016;13(6):2920–2926.27928815
   PubMed Web of Science ®Google Scholar
• Jones J, Follis H, Johnson J. Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era. Prostate Cancer Prostatic Dis. 2009;12(1):57. doi:10.1038/pcan.2008.1418379587
   PubMed Web of Science ®Google Scholar
• Zigeuner RE, Lipsky K, Riedler I, et al. Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. Urology. 2003;62(3):451–455. doi:10.1016/S0090-4295(03)00459-X12946745
   PubMed Web of Science ®Google Scholar
• Yoo C, Oh CY, Kim SJ, et al. Preoperative clinical factors for diagnosis of incidental prostate cancer in the era of tissue-ablative surgery for benign prostatic hyperplasia: A Korean multi-center review. Korean J Urol. 2012;53(6):391–395. doi:10.4111/kju.2012.53.6.39122741046
   PubMedGoogle Scholar
• Sakamoto H, Matsumoto K, Hayakawa N, et al. Preoperative parameters to predict incidental (T1a and T1b) prostate cancer. Can Urol Assoc J. 2014;8(11–12):E815. doi:10.5489/cuaj.189025485009
   PubMed Web of Science ®Google Scholar
• Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A. AJCC Cancer Staging Manual. 7th ed. NY: Springer; 2010.
   Google Scholar
• Andrén O, Fall K, Franzén L, Andersson S-O, Johansson J-E, Rubin MA. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol. 2006;175(4):1337–1340. doi:10.1016/S0022-5347(05)00734-216515993
   PubMed Web of Science ®Google Scholar
• Robinson D, Aus G, Bak J, et al. Long-term follow-up of conservatively managed incidental carcinoma of the prostate A multivariate analysis of prognostic factors. Scand J Urol Nephrol. 2007;41(2):103–109. doi:10.1080/0036559060099126817454947
   PubMed Web of Science ®Google Scholar
• Razzaghi MR, Karkan MF, Ghiasy S, Javanmard B. Laser application in iran urology: a narrative review. J Lasers Med Sci. 2018;9(1):1. doi:10.15171/jlms.2018.0129399302
   PubMed Web of Science ®Google Scholar
• Ghiasy S, Abedi AR, Moradi A, et al. Is active surveillance an appropriate approach to manage prostate cancer patients with Gleason Score 3+ 3 who met the criteria for active surveillance? Turkish J Urol. 2019;45(4):261. doi:10.5152/tud.
   Web of Science ®Google Scholar
• Melchior S, Hadaschik B, Thüroff S, Thomas C, Gillitzer R, Thüroff J. Outcome of radical prostatectomy for incidental carcinoma of the prostate. BJU Int. 2009;103(11):1478–1481. doi:10.1111/bju.2009.103.issue-1119076134
   PubMed Web of Science ®Google Scholar
• Capitanio U, Scattoni V, Freschi M, et al. Radical prostatectomy for incidental (stage T1a–T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Eur Urol. 2008;54(1):118–125. doi:10.1016/j.eururo.2008.02.01818314255
   PubMed Web of Science ®Google Scholar
• Colombo R, Naspro R, Salonia A, et al. Radical prostatectomy after previous prostate surgery: clinical and functional outcomes. J Urol. 2006;176(6):2459–2463. doi:10.1016/j.juro.2006.07.14017085129
   PubMed Web of Science ®Google Scholar
• Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol. 2018;25(6):524–531. doi:10.1111/iju.2018.25.issue-629740894
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Briers E, et al. Guidelines on prostate cancer. Eur Urol. 2014;65(1):124–137. doi:10.1016/j.eururo.2013.09.04624207135
   PubMed Web of Science ®Google Scholar
• Capitanio U, Briganti A, Suardi N, et al. When should we expect no residual tumor (pT0) once we submit incidental T1a‐b prostate cancers to radical prostatectomy? Int J Urol. 2011;18(2):148–153. doi:10.1111/iju.2011.18.issue-221198944
   PubMed Web of Science ®Google Scholar
• Zhao Z, Ma W, Zeng G, Qi D. PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia. J Surg Oncol. 2011;104(6):672–678. doi:10.1002/jso.v104.621674503
   PubMed Web of Science ®Google Scholar
• Abedi A-R, Fallah-karkan M, Allameh F, Ranjbar A, Shadmehr A. Incidental prostate cancer: a 10-year review of a tertiary center, Tehran, Iran. Res Rep Urol. 2018;10:1. doi:10.2147/RRU.S14615929392121
   PubMed Web of Science ®Google Scholar
• Lee LS, Thiruneelakandasivam S, Hong MK, et al. Are transrectal prostate biopsies routinely indicated in patients with incidentally diagnosed prostate cancer following transurethral resection of the prostate for benign disease? Urol Int. 2013;91(4):397–403. doi:10.1159/00035089823921216
   PubMed Web of Science ®Google Scholar
• Javanmard B, Razzaghi MR, Javanbakht O, Karkan MF, Ghiasy S. Pathological Association Between Radical Prostatectomy and Needle Biopsy Specimen in Prostate Cancer Patients. Int J Cancer Manag. 2020;13(1): 1):e91609. doi:10.5812/ijcm.91609
   Web of Science ®Google Scholar
• Visccher D, Cangh V. Assessing the risk of unsuspected prostate cancer in patients with benign prostatic hypertrophy: a 13‐year retrospective study of the incidence and natural history of T1a‐T1b prostate cancers. BJU Int. 1999;84(9):1015–1020. doi:10.1046/j.1464-410x.1999.00386.x10571626
   PubMed Web of Science ®Google Scholar
• Descazeaud A, Peyromaure M, Salin A, et al. Predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era. Eur Urol. 2008;53(2):355–362. doi:10.1016/j.eururo.2007.06.02017611015
   PubMed Web of Science ®Google Scholar
• Chung DY, Goh HJ, Koh DH, et al. Clinical significance of multiparametric MRI and PSA density as predictors of residual tumor (pT0) following radical prostatectomy for T1a-T1b (incidental) prostate cancer. PLoS One. 2018;13(12):e0210037. doi:10.1371/journal.pone.021003730592769
   PubMed Web of Science ®Google Scholar
• Cantrell BB, DeKlerk DP, Eggleston JC, Boitnott JK, Walsh PC. Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. J Urol. 1981;125(4):516–520. doi:10.1016/S0022-5347(17)55092-27218450
   PubMed Web of Science ®Google Scholar
• Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol. 1994;152(5):1721–1729. doi:10.1016/S0022-5347(17)32370-47523719
   PubMed Web of Science ®Google Scholar
• Epstein JI, Paull G, Eggleston JC, Walsh PC. Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. J Urol. 1986;136(4):837–839. doi:10.1016/S0022-5347(17)45097-X3761442
   PubMed Web of Science ®Google Scholar
• Otsubo S, Yokomizo A, Mochida O, et al. Significance of prostate-specific antigen-related factors in incidental prostate cancer treated by holmium laser enucleation of the prostate. World J Urol. 2015;33(3):329–333. doi:10.1007/s00345-014-1310-924804843
   PubMed Web of Science ®Google Scholar
• Bhojani N, Boris RS, Monn MF, Mandeville JA, Lingeman JE. Coexisting prostate cancer found at the time of holmium laser enucleation of the prostate for benign prostatic hyperplasia: predicting its presence and grade in analyzed tissue. J Endourol. 2015;29(1):41–46. doi:10.1089/end.2014.035925046691
   PubMed Web of Science ®Google Scholar
• Ohwaki K, Endo F, Shimbo M, Fujisaki A, Hattori K. Comorbidities as predictors of incidental prostate cancer after Holmium laser enucleation of the prostate: diabetes and high-risk cancer. Aging Male. 2017;20(4):257–260. doi:10.1080/13685538.2017.130141728332895
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53(1):68–80. doi:10.1016/j.eururo.2007.09.00217920184
   PubMed Web of Science ®Google Scholar
• Liu Z, Luo C, Hu S, et al. Diagnosis and treatment of T1a-T1b prostate cancer. J Peking Univ Health Sci. 2016;48(5):812–816.
   Google Scholar
• Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol. 2018;199(3):683–690. doi:10.1016/j.juro.2017.11.09529203269
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59(1):61–71. doi:10.1016/j.eururo.2010.10.03921056534
   PubMed Web of Science ®Google Scholar
• Karkan MF, Razzaghi MR, Javanmard B, Tayyebiazar A, Ghiasy S, Montazeri S. Holmium: YAG laser incision of bladder neck contracture following radical retropubic prostatectomy. Nephro-Urol Mon. 2020;11(1):e88677. doi:10.5812/numonthly.88677
   Google Scholar
• Helfand BT, Mongiu AK, Kan D, et al. Outcomes of radical prostatectomy for patients with clinical stage T1a and T1b disease. BJU Int. 2009;104(3):304–309. doi:10.1111/j.1464-410X.2009.08421.x19239451
   PubMed Web of Science ®Google Scholar
• Allameh F, Azghandi S, Karkan MF. Is chemotherapy related with erectile dysfunction in non-urologic cancer patients? Int J Cancer Manage. 2018. doi:10.5812/ijcm.82529
   Web of Science ®Google Scholar
• Allameh F, Rahavian AH, Ghiasy S. Prevalence of castration success rate in Iranian metastatic prostate cancer patients: A referral center statistics Int J Cancer Manag. 2018 Oct;11(10)e83613. doi:10.5812/ijcm.83613
   Google Scholar
• Paul R, Knebel C, Kübler H, Alschibaja M, Günther M, Hartung R. Incidental carcinoma of the prostate: can we and should we recommend radical prostatectomy? Der Urologe Ausg A. 2005;44(9):1052,4–8.15965641
   PubMedGoogle Scholar
• Gacci M, Simonato A, Lanciotti M, et al. The impact of prior TURP on radical prostatectomy surgical margins: a multicenter analysis. Urol Int. 2013;91(1):62–68. doi:10.1159/00034674823735440
   PubMed Web of Science ®Google Scholar
• Jaffe J, Stakhovsky O, Cathelineau X, Barret E, Vallancien G, Rozet F. Surgical outcomes for men undergoing laparoscopic radical prostatectomy after transurethral resection of the prostate. J Urol. 2007;178(2):483–487. doi:10.1016/j.juro.2007.03.11417561162
   PubMed Web of Science ®Google Scholar
• Katz R, Borkowski T, Hoznek A, Salomon L, Gettman MT, Abbou CC. Laparoscopic radical prostatectomy in patients following transurethral resection of the prostate. Urol Int. 2006;77(3):216–221. doi:10.1159/00009481217033208
   PubMed Web of Science ®Google Scholar
• Yang Y, Luo Y, Hou G-L, et al. Laparoscopic radical prostatectomy after previous transurethral resection of the prostate in clinical T1a and T1b prostate cancer: a matched-pair analysis. Urol J. 2015;12(3):2154–2159.26135931
   PubMed Web of Science ®Google Scholar
• Menard J, de la Taille A, Hoznek A, et al. Laparoscopic radical prostatectomy after transurethral resection of the prostate: surgical and functional outcomes. Urology. 2008;72(3):593–597. doi:10.1016/j.urology.2008.03.01918762050
   PubMed Web of Science ®Google Scholar
• Teber D, Cresswell J, Ates M, et al. Laparoscopic radical prostatectomy in clinical T1a and T1b prostate cancer: oncologic and functional outcomes—a matched-pair analysis. Urology. 2009;73(3):577–581. doi:10.1016/j.urology.2008.09.05919100598
   PubMed Web of Science ®Google Scholar
• Elder JS, Gibbons RP, Correa RJ, Brannen GE. Morbidity of radical perineal prostatectomy following transurethral resection of the prostate. J Urol. 1984;132(1):55–57. doi:10.1016/S0022-5347(17)49462-66726961
   PubMed Web of Science ®Google Scholar
• Zugor V, Labanaris AP, Porres D, Witt JH. Surgical, oncologic, and short-term functional outcomes in patients undergoing robot-assisted prostatectomy after previous transurethral resection of the prostate. J Endourol. 2012;26(5):515–519. doi:10.1089/end.2011.020521913854
   PubMed Web of Science ®Google Scholar
• Guilhen M, Hennequin C, Ouzaid I, et al. Urinary function and quality of life after radiotherapy for prostate cancer in patients with prior history of surgical treatment for benign prostatic hyperplasia. Radiat Oncol. 2018;13(1):209. doi:10.1186/s13014-018-1149-030355359
   PubMed Web of Science ®Google Scholar
• Devisetty K, Zorn KC, Katz MH, Jani AB, Liauw SL. External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity. Int J Radiat Oncol Biol Phys. 2010;77(4):1060–1065. doi:10.1016/j.ijrobp.2009.06.07820045267
   PubMed Web of Science ®Google Scholar
• Lee WR, Schultheiss TE, Hanlon AL, Hanks GE. Urinary incontinence following external-beam radiotherapy for clinically localized prostate cancer. Urology. 1996;48(1):95–99. doi:10.1016/S0090-4295(96)00085-48693660
   PubMed Web of Science ®Google Scholar
• Perez CA, Lee HK, Georgiou A, Lockett MA. Technical factors affecting morbidity in definitive irradiation for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1994;28(4):811–819. doi:10.1016/0360-3016(94)90100-78138433
   PubMed Web of Science ®Google Scholar
• Perez CA, Walz BJ, Zivnuska FR, Pilepich M, Prasad K, Bauer W. Irradiation of carcinoma of the prostate localized to the pelvis: analysis of tumor response and prognosis. Int J Radiat Oncol Bio Phys. 1980;6(5):555–563. doi:10.1016/0360-3016(80)90382-X7410129
   PubMed Web of Science ®Google Scholar
• Sandhu AS, Zelefsky MJ, Lee HJ, Lombardi D, Fuks Z, Leibel SA. Long-term urinary toxicity after 3-dimensional conformal radiotherapy for prostate cancer in patients with prior history of transurethral resection. Int J Radiat Oncol Biol Phys. 2000;48(3):643–647. doi:10.1016/S0360-3016(00)00714-811020559
   PubMed Web of Science ®Google Scholar
• Ishiyama H, Hirayama T, Jhaveri P, et al. Is there an increase in genitourinary toxicity in patients treated with transurethral resection of the prostate and radiotherapy?: a systematic review. Am J Clin Oncol. 2014;37(3):297–304. doi:10.1097/COC.0b013e318254682122706173
   PubMed Web of Science ®Google Scholar
• Zapatero A, Roch M, Büchser D, et al. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer. Clin Transl Oncol. 2017;19(9):1161–1167. doi:10.1007/s12094-017-1655-928374321
   PubMed Web of Science ®Google Scholar
• Chevli C, Narayanan R, Rambarran L, Kubicek G, Chevli KK, Duff M. Effect of pretreatment prostate volume on urinary quality of life following intensity-modulated radiation therapy for localized prostate cancer. Res Rep Urol. 2013;5:29.24400232
   PubMedGoogle Scholar
• Polland A, Vertosick EA, Sjoberg DD, et al. Preoperative symptoms predict continence after post-radiation transurethral resection of prostate. Can J Urol. 2017;24(4):8903–8909.28832309
   PubMed Web of Science ®Google Scholar